Condensed Consolidated Statements of Cash Flows Statement - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net Loss, Including Portion Attributable to Noncontrolling Interest	$ (40,128)	$ (50,521)
Adjustments to reconcile net loss including noncontrolling interests in operating subsidiaries to net cash used in operating activities:
Depreciation and amortization	40,129	43,753
Non-cash stock compensation	8,588	14,022
Net cash used in operating activities	2,155	13,890
Cash flows from investing activities:
Maturities and sale of available-for-sale investments	82,115	133,878
Purchase of available-for-sale investments	(23,296)	(76,130)
Investments in patents/ patent rights	(19,504)	(24,518)
Purchases of property and equipment	(8)	(106)
Net cash provided by investing activities	39,307	33,124
Cash flows from financing activities:
Payments of Dividends	(19,091)	(18,773)
Distributions to noncontrolling interests in operating subsidiary	0	867
Proceeds from exercises of stock options	938	198
Net cash used in financing activities	(18,153)	(19,442)
Increase (decrease) in cash and cash equivalents	23,309	27,572
Cash and cash equivalents, beginning	134,466	126,685
Cash and cash equivalents, ending	157,775	154,257
Patent acquisition costs included in accrued patent acquisition costs	0	2,000
Changes in assets and liabilities:
Restricted cash	(10,721)	0
Accounts receivable	7,411	(6,361)
Prepaid expenses and other assets	(569)	1,719
Accounts payable and accrued expenses	2,680	5,503
Royalties and contingent legal fees payable	(5,108)	7,330
Deferred income tax	0	(1,531)
Other	$ (127)	$ (24)